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Summary
The clinical course of chronic lymphocytic leukaemia (CLL) is heteroge-
neous, and treatment options vary considerably. The Connect CLL reg-
istry is a multicentre, prospective observational cohort study that provides
a real-world perspective on the management of, and outcomes for, patients
with CLL. Between 2010 and 2014, 1494 patients with CLL and that
initiated therapy, were enrolled from 199 centres throughout the USA (179
community-, 17 academic-, and 3 government-based centres). Patients were
grouped by line of therapy at enrolment (LOT). We describe the clinical
and demographic characteristics of, and practice patterns for, patients with
CLL enrolled in this treatment registry, providing patient-level observa-
tional data that represent real-world experiences in the USA. Fluorescence
in situ hybridization (FISH) analyses were performed on 493% of patients
at enrolment. The most common genetic abnormalities detected by FISH
were del(13q) and trisomy 12 (457% and 208%, respectively). Differences
in disease characteristics and comorbidities were observed between patients
enrolled in LOT1 and combined LOT2/≥3 cohorts. Important trends
observed include the infrequent use of genetic prognostic testing, and dif-
ferences in patient characteristics for patients receiving chemoimmunother-
apy combinations. These data represent experiences of patients with CLL in
the USA, which may inform treatment decisions in everyday practice.
Keywords: chronic lymphocytic leukaemia, practice patterns, patient
characteristics, Connect CLL Registry, chemoimmunotherapy.
Chronic lymphocytic leukaemia (CLL) is the most common
adult leukaemia in Western countries. Considerable advances
have been made in our understanding of the biology of CLL
and use of prognostic markers to predict disease progression
and therapeutic outcomes. Although diagnostic and prognos-
tic testing is recommended (Hallek et al, 2008; National
Comprehensive Cancer Network, 2014; https://www.nc
cn.org/), interpretation of international guidelines still varies
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considerably, specifically regarding when to initiate CLL ther-
apy, how to apply prognostic factors when making treatment
choices, and the type and sequence of therapeutic regimen
offered to patients (Hallek, 2013; Cuneo et al, 2014; Mertens
& Stilgenbauer, 2014). Although the results of testing for
immunoglobulin heavy chain locus (IGHV) and fluorescence
in situ hybridization (FISH) have been shown to predict sur-
vival in patients with CLL (Parikh et al, 2016) they are not
recommended to be used to drive treatment initiation deci-
sions (Hallek et al, 2008). However, such testing could guide
follow-up intervals for high-risk patients (Parikh et al, 2016).
CLL is a disease that predominantly affects elderly people,
and the management of elderly patients with CLL is more
complex than that of younger patients due to a greater fre-
quency of comorbidities (Altekruse et al, 2010; Smith et al,
2011; Siegel et al, 2014). Furthermore, differences in patient
outcomes can exist between those treated in clinical trials
and those treated in clinical practice: patients in clinical trials
may be younger, have fewer comorbidities, more favourable
Eastern Cooperative Oncology Group Performance Status
(ECOG PS), or different racial and/or socioeconomic profiles
(Abel, 2011). Therefore, the treatments offered to patients
with CLL and the resulting outcomes may vary considerably
between institutions, as well as between academic and com-
munity settings. As the number of novel agents available for
the treatment of CLL expand, these results are particularly
relevant in order to foster a more collaborative approach in
the diagnosis and treatment of CLL.
The Connect CLL registry was established to gather
information about the experiences of patients undergoing
treatment for CLL. To our knowledge, it is the largest
prospective disease registry to date, and focuses on the clini-
cal courses of patients being treated for CLL at multiple
study centres in the USA. The primary objective of the Regis-
try is to observe the treatment patterns for patients with
CLL. Here we describe the clinical and demographic charac-
teristics of patients included in the Connect CLL registry, as
well as the treatment patterns of enrolling physicians from
community-, academic- and government-based centres.
Patients and methods
Study design and participants
The Connect CLL registry (NCT01081015) is a multicentre,
prospective observational cohort study. A central Institu-
tional Review Board (IRB) (Quorum Review IRB, Seattle,
WA, USA) approved the study protocol and was used by 100
centres for site-specific approval; the remaining centres used
their local IRB. Study centres with experience in oncology/
haematology trials/registries, access to high-speed internet,
and adequate numbers of patients with CLL were selected;
each centre could enrol a maximum of 30 patients. Sites
were encouraged to enrol all eligible patients as they pre-
sented to their physician.
Patients were required to be aged ≥18 years, provide writ-
ten informed consent, and have CLL as defined by the Inter-
national Workshop on Chronic Lymphocytic Leukaemia
(IWCLL) guidelines (Hallek et al, 2008). Only patients who
initiated a line of therapy (LOT) within 2 months prior to
study enrolment were eligible for inclusion. Patients were
enrolled into one of three cohorts based on the LOT initi-
ated: ‘LOT1’ (first-line); ‘LOT2’ (second-line); and ‘LOT≥3’
(third-line or above). Each patient was to be followed for up
to 5 years or until early discontinuation (i.e., due to death,
withdrawal of consent, loss to follow-up, or study termina-
tion). Follow-up data were to be collected approximately
every 3 months during study participation.
The Connect CLL registry is observational, with all inter-
ventions and scheduled visits performed solely at the discre-
tion of the treating physician in accordance with their usual
care. Participation in the registry is voluntary; patients can
withdraw at any time without affecting their subsequent
medical care. Patients can receive compensation for comple-
tion of the health-related quality of life (HRQoL) question-
naires ($10 per questionnaire) if reimbursement is approved
by their IRB.
Assessments
Information was collected at enrolment via an electronic data
capture system, and included demographic information, rele-
vant medical history, laboratory testing, available diagnostic
and prognostic testing [i.e., metaphase cytogenetics (MC)
and FISH], flow cytometry analyses (CD38 and ZAP70
expression), and HRQoL.
Every 3 months, centre personnel record protocol-speci-
fied, relevant data retrieved from patient medical records. In
addition, patients are asked to complete HRQoL instruments
at enrolment and every 3 months during follow-up.
Statistical analysis
Date of enrolment was considered the baseline for this study.
Only laboratory samples collected no more than 7 days
before the start of enrolment therapy were used for baseline
laboratory testing. Medical history and pre-existing condition
data were used to generate a Charlson Comorbidity Index
(CCI) score for use as a prognostic indicator of overall risk
of death due to comorbidities and to assess the burden of
comorbidities at registry enrolment (Charlson et al, 1987).
All data entered as of 25 December 2014 were included in
this analysis. Survival data were updated as of 25 August
2015.
Statistical analyses to assess differences in characteristics at
enrolment between patient subgroups of interest were con-
ducted using a Chi-square test for the comparison of rates
and a Wilcoxon two-sample test for the comparison of medi-
ans. Logistic regression was used to assess the role of ECOG
PS and CCI scores adjusted for LOT and age, and to identify
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factors predicting MC or FISH testing. Patients with MC or
FISH data were compared with those who did not have a
result or were not tested. Univariate logistic regression was
utilized to screen covariates; those significant at the 015 level
were evaluated in the multivariate setting. All possible logistic
regression models were run and the best fitting model was
selected using the score statistic. Missing data were not
imputed as per registry protocol. In the statistical analyses,
missing data was assumed to be missing at random; sensitiv-
ity analyses were conducted where appropriate.
The Kaplan–Meier method was used to estimate overall
survival (OS) by LOT and P-values from the log-rank test
for comparison of survival distributions were provided. OS
was defined as the interval between the start of enrolment
therapy and the date of death; subjects who did not have a
date of death were censored at the last date at which they
were known to be alive, at study discontinuation or at the
data cut-off date, whichever was earliest.
All statistical significance was assessed at a 5% level (two-
sided). Statistical analyses of all data were performed using
SAS version 9.2 statistical software (SAS Institute, Cary,
NC, USA).
Results
Patient population
Between March 2010 and January 2014, 1494 patients were
enrolled in the Connect CLL Registry, from 199 centres
throughout the USA (179 community-, 17 academic- and 3
government-based centres). Of these, 1311 (878%), 155
(104%), and 28 (19%) patients were enrolled at commu-
nity-, academic- and government-based centres, respectively.
Of the total population, 889 were in LOT1, 260 were in
LOT2 and 345 were in LOT≥3. Patient enrolment in aca-
demic versus community centres was balanced across LOT
groups. 1449 patients completed the HRQoL questionnaire at
enrolment.
Table I provides demographics and characteristics of the
total population by LOT at study enrolment. The median
age of patients was 69 years (range 22–99), with 512 (343%)
patients aged ≥65 to <75 years and 455 (305%) ≥75 years.
All patients had a clinical diagnosis of CLL; this diagnosis
was confirmed by flow cytometry in 949% of patients (i.e.,
positive for CD5 and ≥1 of CD19, CD20 or CD23).
Disease characteristics at study enrolment are presented by
LOT in Table II; Table SI shows data by patient age. Rai
stage was recorded in 1075 (72%) patients. In patients with
recorded symptoms, the most frequent constitutional symp-
tom in all age groups was fatigue. Haematology data strati-
fied by Rai stage at enrolment are shown in Table SII.
Differences in characteristics at registry enrolment were
observed between patients in LOT1 and the combined LOT2/
≥3 cohorts, as follows: median age was lower in LOT1
patients, an ECOG PS of 0 was more frequent, and CCI
scores of ≥3 were less frequent. Functional Assessment of
Cancer Therapy–Leukaemia (FACT-Leu) median HRQoL
scores at enrolment were also higher in the LOT1 cohort
than in LOT2/LOT≥3 (1380 vs. 1342, respectively) and in
the Functional Assessment of Cancer Therapy–General
(FACT-G) total scores (880 vs. 853, respectively)
(Table SIII).
Characteristics also differed by type of treating institu-
tion. The median age of patients treated at academic versus
community/government centres was 63 years vs. 70 years
(P < 00001). Significantly more patients at academic cen-
tres had CCI scores ≤2 than those at community/govern-
ment centres (684% vs. 534%; P = 00004). They also
had significantly higher estimated creatinine clearance
(CrCl) than those treated at community/government cen-
tres (medians 869 ml/min vs. 720 ml/min; P = 0001). In
the German CLL Study Group CLL8 (Cramer et al, 2013)
and CLL10 (Eichhorst et al, 2014) trials, ‘fitness’ of
patients eligible for intensive chemoimmunotherapy (CIT)
regimens were defined as those with CCI scores ≤2, CrCl
≥70 ml/min and ECOG PS ≤1. Applying this definition to
our study population, we found that 20% of patients aged
<75 years met the criteria; when stratified by LOT, 23% of
LOT1 and 14% of LOT2 patients met the criteria. Across
institution types, we found that a disproportionate number
of the ‘fit’ patients were enrolled at academic centres
rather than community/government centres (35% vs. 18%)
(Sharman et al, 2014a).
Prognostic information and practice patterns
Fewer than 20% of patients were tested for ZAP70 or CD38
expression at study enrolment (Table III). MC analyses, most
frequently of bone marrow aspirate, were performed in
362% of patients, and trisomy 12 (176%) and del(13q)
(142%) were the most commonly detected abnormalities.
FISH was performed in 493% of patients at enrolment, with
del(13q) (457%) and trisomy 12 (208%) being the most
commonly detected abnormalities. Of the 889 patients in
LOT1, 65% (n = 576) were tested by MC and/or FISH
before enrolment, as were 50% (n = 130) of LOT2 patients,
and 45% (n = 155) of LOT≥3 patients. Of the 861 patients
overall who were tested at enrolment, 40% of those who pro-
gressed had MC and/or FISH analyses retested with a subse-
quent LOT.
Significant differences in MC/FISH prognostic testing rates
were observed between patients in LOT1 and patients in
LOT2/≥3 (648% vs. 471%, respectively; P < 00001); there-
fore, further analyses stratifying by LOT1 versus LOT2/≥3
were performed. In univariate logistic regression analyses of
LOT1 patients, 5 of 12 potential prognostic or social predic-
tors were significantly associated with performing MC or
FISH: Rai stage ≥II; age ≤75 years; private insurance; white
race; and treating-institution type (academic versus commu-
nity/government centre) (Mato et al, 2015). In multivariate
A. Mato et al
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analysis, treating-institution type, race, and insurance status
remained significant independent predictors of MC/FISH
testing at LOT1. When the analysis was performed within
the subset of patients enrolled at community/government
centres only, age, race and Rai stage were independent signif-
icant predictors of performing prognostic testing (Table IV)
(Mato et al, 2015).
Survival outcomes and CLL disease history and therapy
The median time from diagnosis to study entry (for any
LOT) was 37 months (range 0–390). Figure 1 depicts the OS
estimates for the fully enrolled Connect CLL. Median follow-
up was 366 months (range 1–65) in LOT1, 288 months
(range 0–63) in LOT2 and 258 months (range 0–62) in
Table I. Patient demographics and characteristics at enrolment to the registry.
LOT1
(n = 889)
LOT2
(n = 260)
LOT≥3
(n = 345)
All patients
(N = 1494)
Age, years
Mean (SD) 676 (110) 699 (112) 690 (98) 683 (108)
Median (range) 680 (22–99) 710 (34–96) 690 (34–93) 690 (22–99)
Age, n (%)
<65 years 335 (377) 83 (319) 109 (316) 527 (353)
≥65 to <75 years 295 (332) 82 (315) 135 (391) 512 (343)
≥75 years 259 (291) 95 (365) 101 (293) 455 (305)
Sex, n (%)
Male 566 (637) 171 (658) 216 (626) 953 (638)
Female 323 (363) 89 (342) 129 (374) 541 (362)
Duration of CLL from diagnosis to
enrolment, median (range), months
15 (0–390) 60 (1–339) 96 (5–380) 37 (0–390)
Race, n (%) n = 863 n = 250 n = 331 N = 1444
White 798 (925) 234 (936) 301 (909) 1333 (923)
Black 56 (65) 14 (56) 28 (85) 98 (68)
Other 6 (07) 1 (04) 1 (03) 8 (06)
American Indian/Alaskan native 0 1 (04) 0 1 (01)
Asian 3 (03) 0 1 (03) 4 (03)
United States geographic region, n (%) n = 881 n = 259 n = 343 N = 1483
Northeast 112 (127) 41 (158) 54 (157) 207 (140)
Midwest 277 (314) 68 (263) 114 (332) 459 (310)
South 352 (400) 113 (436) 126 (367) 591 (399)
West 140 (159) 37 (143) 49 (143) 226 (152)
Institution type, n (%)
Academic 86 (97) 28 (108) 41 (119) 155 (104)
Community 787 (885) 227 (873) 297 (861) 1311 (878)
Government 16 (18) 5 (19) 7 (20) 28 (19)
Insurance type, n (%)*
Medicare 512 (576) 170 (654) 232 (672) 914 (612)
Medicaid 42 (47) 11 (42) 12 (35) 65 (44)
Supplemental coverage 178 (200) 60 (231) 88 (255) 326 (218)
Private health insurance 403 (453) 99 (381) 125 (362) 627 (420)
Health maintenance organization 104 (117) 31 (119) 38 (110) 173 (116)
Preferred provider organization 232 (261) 54 (208) 63 (183) 349 (234)
Other 68 (76) 16 (62) 25 (72) 109 (73)
Military 15 (17) 3 (12) 8 (23) 26 (17)
Self-pay 13 (15) 3 (12) 3 (09) 19 (13)
Other insurance 13 (15) 3 (12) 8 (23) 24 (16)
Not specified 20 (22) 13 (50) 8 (23) 41 (27)
History of CLL in immediate family, n (%) n = 741 n = 208 n = 265 N = 1214
Yes 37 (50) 15 (72) 23 (87) 75 (62)
No 704 (950) 193 (928) 242 (913) 1139 (938)
CLL, chronic lymphocytic leukaemia; LOT, line of therapy; SD, standard deviation.
*Patients can be covered by multiple insurance plans.
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LOT≥3. Median OS has not been reached for LOT1 and
LOT2 cohorts. For patients in the LOT1 group, the most
common reasons for treatment initiation at enrolment to the
registry were progressive marrow failure (399%) and massive
bulky or progressive lymphadenopathy (371%).
The most commonly used treatment approach across all
cohorts and all age groups was CIT, which was prescribed to
a total of 895 patients (599%) (Table V). Chlorambucil-
based therapy was infrequently prescribed in the total popu-
lation and across all LOTs (~4%). In LOT1 patients, the
most commonly prescribed therapies were purine analogue-
based (374%) and bendamustine-based (227%) CITs,
although with increasing patient age a decreased use of pur-
ine analogue-based CIT was observed in favour of ben-
damustine-based CIT and anti-CD20 monoclonal antibody
therapies. Overall, in LOT2 patients, bendamustine-based
CIT combinations were the most frequently prescribed thera-
pies (289%), particularly in patients aged ≥65 to <75 years
(378%). LOT2 patients aged ≥75 years received purine ana-
logue-based CIT and anti-CD20 monoclonal antibody
monotherapies most frequently. LOT≥3 patients also received
CIT combinations most frequently (435% overall; with
293% bendamustine-based CIT and 104% purine analogue-
based CIT). A variety of purine analogue-based regimens
were used (Table VI). Across all LOTs, patients were infre-
quently enrolled into clinical trials; in LOT1, 30 patients
(34%) were enrolled into clinical trials compared with 5
(19%) in LOT2 and 5 (46%) in LOT≥3 (Table V).
Discussion
The majority of patients in the Connect CLL registry were
treated at community-based centres. As such, the registry
provides detailed, patient-level observational data of a diverse
population of patients with CLL who would, on the whole,
be unsuitable for stringent clinical trials.
Overall, the Connect CLL registry appears to be generally
representative of the US CLL population. The median age of
patients enrolled in the Connect CLL registry was 69 years
whereas the median age of patients at diagnosis reported in
the Surveillance, Epidemiology, and End Results (SEER) Pro-
gram was 71 years (Altekruse et al, 2010). There was a high
proportion of older patients (65% ≥65 years) in the Connect
CLL registry, allowing for more detailed analyses across age
Table II. Clinical characteristics at enrolment to the registry.
LOT1 (n = 889) LOT2 (n = 260) LOT≥3 (n = 345) All patients (N = 1494)
ECOG PS, n (%) n = 689 n = 182 n = 250 N = 1121
0: Fully active 346 (502) 77 (423) 103 (412) 526 (469)
1: Restricted in strenuous activity only 296 (430) 93 (511) 124 (496) 513 (458)
2: Ambulatory, but unable to work 41 (60) 11 (60) 20 (80) 72 (64)
3: Capable of only limited self-care 5 (07) 1 (05) 3 (12) 9 (08)
4: Completely disabled 1 (01) 0 0 1 (01)
Rai staging system, n (%) n = 684 n = 172 n = 219 N = 1075
Stage 0 172 (251) 53 (308) 56 (256) 281 (261)
Stage I 191 (279) 35 (203) 62 (283) 288 (268)
Stage II 108 (158) 32 (186) 27 (123) 167 (155)
Stage III 107 (156) 28 (163) 40 (183) 175 (163)
Stage IV 106 (155) 24 (140) 34 (155) 164 (153)
Binet staging system, n (%) n = 109 n = 23 n = 25 N = 157
Stage A 30 (275) 7 (304) 9 (360) 46 (293)
Stage B 42 (385) 8 (348) 5 (200) 55 (350)
Stage C 37 (339) 8 (348) 11 (440) 56 (357)
Constitutional symptoms,* n (%) n = 580 n = 174 n = 216 N = 970
Fatigue 480 (828) 148 (851) 178 (824) 806 (831)
Fever 60 (103) 12 (69) 15 (69) 87 (90)
Night sweats 226 (390) 59 (339) 53 (245) 338 (348)
Other 113 (195) 42 (241) 37 (171) 221 (228)
Weight loss 157 (271) 55 (316) 53 (245) 236 (243)
Nodal bulk (≥5 cm), n/N† (%)
Head and neck 34/777 (44) 5/221 (23) 9/281 (32) 48/1279 (38)
Axillae 36/717 (50) 8/198 (40) 16/275 (58) 60/1190 (50)
Groin 16/527 (30) 8/152 (40) 4/200 (20) 28/879 (32)
CCI score, median (range) 20 (20–100) 20 (20–90) 20 (20–130) 20 (20–130)
CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LOT, line of therapy.
*All relevant constitutional symptoms could be checked.
†n refers to the number of patients testing positive. N refers to the total number of patients with recorded lymph node data.
A. Mato et al
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groups. The ratio of white to black patients was similar to
that reported in SEER registries (Shenoy et al, 2011). The
majority of patients (88%) were being cared for at commu-
nity-based centres and outside the context of interventional
clinical trials, thereby allowing insight into more typical,
community-based management of CLL.
Genomic aberrations in CLL are important predictors of
disease progression and survival, and unfavourable prognostic
markers can be easily identified using MC or FISH (Damle
et al, 1999; Hamblin et al, 1999; D€ohner et al, 2000). The
National Comprehensive Cancer Network (National Compre-
hensive Cancer Network, 2014; https://www.nccn.org/), the
IWCLL (Hallek et al, 2008) guidelines, and a recent meta-ana-
lysis of genetic testing in newly diagnosed CLL (Parikh et al,
2016) recommend prognostic testing, such as FISH and
IGHV, in the management of patients with CLL. As genetic
defects may be acquired as the disease progresses, repeat test-
ing prior to each line of therapy may be useful (Hallek et al,
2008); however, limited information exists about how these
guidelines are interpreted in practice. In Connect CLL, genetic
testing by MC and FISH was performed in only 39% and 58%
of patients before LOT1, respectively; only 64% of patients
across all LOTs were tested for IGHV somatic hypermutation.
Additionally, only 40% of patients tested at enrolment and
who progressed were retested by MC and/or FISH with a sub-
sequent LOT. These data may suggest a dearth of routine
genetic testing in the community as a means of guiding treat-
ment selection; however, as this is an observational study,
underreporting or missing data could partially explain these
lower diagnostic testing rates.
Table III. Prognostic factors at enrolment to the registry.
LOT1 (n = 889) LOT2 (n = 260) LOT≥3 (n = 345) All patients (N = 1494)
MC analysis performed*
Yes 347 (390) 81 (312) 113 (328) 541 (362)
Abnormalities found 158 (455) 37 (457) 67 (593) 262 (484)
del(11q) 36 (104) 6 (74) 17 (150) 59 (109)
del(13q) 47 (135) 11 (136) 19 (168) 77 (142)
del(17p) 19 (55) 3 (37) 12 (106) 34 (63)
Trisomy 12 57 (164) 14 (173) 24 (212) 95 (176)
No 464 (522) 144 (554) 189 (548) 797 (533)
Not specified 78 (88) 35 (135) 43 (125) 156 (104)
FISH analysis performed
Yes 513 (577) 105 (404) 119 (345) 737 (493)
Abnormalities found 380 (741) 67 (638) 93 (782) 540 (733)
del(11q) 90 (175) 19 (181) 26 (218) 135 (183)
del(13q) 238 (464) 43 (410) 56 (471) 337 (457)
del(17p) 51 (99) 12 (114) 25 (210) 88 (119)
Trisomy 12 105 (205) 20 (190) 28 (235) 153 (208)
No 325 (366) 132 (508) 186 (539) 643 (430)
ZAP70 performed
Yes 203 (228) 43 (165) 47 (136) 293 (196)
ZAP70 positive 115 (567) 22 (512) 33 (702) 170 (580)
ZAP70 negative 77 (379) 19 (442) 13 (277) 109 (372)
Not evaluable/specified 11 (55) 2 (46) 1 (21) 14 (47)
No 686 (772) 217 (835) 298 (864) 1201 (804)
CD38 performed
Yes 189 (213) 38 (146) 34 (99) 261 (175)
CD38 positive 77 (407) 16 (421) 16 (471) 109 (418)
CD38 negative 105 (556) 21 (553) 15 (441) 141 (540)
Not evaluable/specified 7 (37) 1 (26) 3 (88) 11 (42)
No 700 (787) 222 (854) 311 (901) 1233 (825)
IGVH performed
Yes 70 (79) 13 (50) 10 (29) 93 (62)
IGVH mutated 25 (357) 3 (231) 2 (200) 30 (20)
IGVH unmutated 45 (643) 9 (692) 8 (800) 62 (41)
Not evaluable/specified 0 (0) 1 (77) 0 (0) 1 (< 01)
No 819 (921) 247 (950) 335 (971) 1401 (938)
All values are n (%).
FISH, fluorescence in situ hybridization; LOT, line of therapy; MC, metaphase cytogenetics.
*No refers to patients for whom test results were negative. Not specified refers to patients for whom data is missing or was not completed.
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The importance of FISH testing before therapy selection is
highlighted in the inclusion criteria of recent CIT clinical tri-
als. In CLL10 (Eichhorst et al, 2013), for example, and in
ongoing front-line studies comparing CIT approaches with
kinase inhibitors (NCT02048813; NCT01886872), patients
with del(17p) are excluded due to the poor outcomes
expected with CITs. More recent data, however, from
patients receiving ibrutinib or idelalisib with rituximab,
demonstrate that these agents may, in part, overcome tradi-
tional unfavourable characteristics such as del(17p) (Byrd
et al, 2014; Furman et al, 2014; O’Brien et al, 2014; Sharman
et al, 2014b). Nevertheless, even with these newer targeted
agents, patients with high-risk FISH cytogenetics are shown
to relapse more quickly than their low-risk counterparts.
Recent data also demonstrate the value of MC in the risk
stratification of ibrutinib-treated patients (Thompson et al,
2014). In the current era of targeted therapies, the presence
of certain genetic abnormalities may be of relevance when
personalizing therapies. Now that kinase inhibitors are widely
available, it will be important to observe if the use of genetic
testing will dramatically affect treatment selection in Connect
CLL participants.
Differences observed between clinical trial participants and
the community-based CLL population raise the question as
to whether promising results obtained from clinical trials can
be extrapolated to routine practice. Recent data from land-
mark CIT clinical trials, such as CLL8 (Cramer et al, 2013)
and CLL10 (Eichhorst et al, 2014), demonstrate that study
participants treated with CIT regimens, such as fludarabine,
cyclophosphamide, and rituximab (FCR) or bendamustine
and rituximab (BR), are generally younger and have fewer
comorbid conditions than typical patients with CLL (Hallek
et al, 2010; Eichhorst et al, 2013). Specifically, patients
enrolled in CLL8 (FCR versus fludarabine and cyclophos-
phamide) had a median age of 61 years, and only 11% of
patients aged ≥70 years were treated with FCR (Cramer et al,
2013). Similarly, in CLL10 (FCR versus BR), the median age
was 62 years and the median Cumulative Illness Rating Scale
(CIRS) score was 2 (Eichhorst et al, 2014). CIRS scores were
not captured in our analysis, although we did calculate CCI
scores, which are reported to provide reasonable correlation
with the CIRS as objective estimates of medical comorbidity
(Extermann et al, 1998). Although the median CCI score in
the Connect CLL registry was 2, 45% of patients had CCI
≥3, which signifies the presence of multiple comorbid condi-
tions and predicts a 10-year mortality of 59% attributable to
comorbid disease (Charlson et al, 1987).
Many would argue that CIT combinations, particularly
FCR, are the standard of care in the front-line treatment of
fit patients with CLL, yet only 454% of patients <75 years of
age in the Connect CLL registry were treated with purine
analogue-based CIT in the LOT1 cohort. When considering
the inclusion criteria for patients in studies such as CLL8
and CLL10, we estimated that only 20% of patients in the
Connect CLL registry would have been considered suitable
study candidates. Therefore, our CIT-treated population
appears different to that of the CLL8 and CLL10 trials (Cra-
mer et al, 2013; Eichhorst et al, 2014), and may provide
Table IV. Multivariate analysis: independent predictors of perform-
ing MC/FISH analyses in LOT1 patients.
Institution type Covariate OR (95% CI)
All centres Academic versus community/
government centre
176 (103–299)
White versus other ethnicity 190 (113–317)
Private insurance versus other 144 (108–192)
Community/
government
centres
White versus other ethnicity 240 (126–458)
<75 versus ≥75 years of age 144 (101–205)
Rai stage ≥II versus ≤I 152 (107–214)
CI, confidence interval; FISH, fluorescence in situ hybridization;
LOT, line of therapy; MC, metaphase cytogenetics; OR, odds ratio.
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Fig 1. Kaplan–Meier curves of overall survival
stratified by LOT. Data cut-off: 25 August
2015. CI, confidence interval; LOT, line of
therapy.
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Table V. All therapy categories at enrolment to the registry.
Patients, age (years) Therapy prescribed at enrolment
LOT1 LOT2 LOT≥3 Overall
N n (%) N n (%) N n (%) N n (%)
All CIT 889 588 (661) 260 157 (604) 345 150 (435) 1,494 895 (599)
Purine analogue-based CIT 332 (374) 65 (250) 36 (104) 433 (290)
Bendamustine-based CIT 202 (227) 75 (289) 101 (293) 378 (253)
Chlorambucil-based CIT 10 (11) 0 1 (03) 11 (07)
CHOP/CVP/CTX-based CIT 33 (37) 13 (50) 9 (26) 55 (37)
Other CIT 11 (12) 4 (15) 3 (09) 18 (12)
Chemotherapy 91 (102) 26 (100) 35 (101) 152 (102)
Chlorambucil monotherapy 41 (46) 6 (23) 11 (32) 58 (39)
Anti-CD20 mAb monotherapy 116 (131) 45 (173) 72 (209) 233 (156)
Rituximab monotherapy 104 (117) 38 (146) 44 (128) 186 (124)
Ofatumumab monotherapy 5 (06) 2 (08) 23 (67) 30 (20)
Kinase inhibitor therapies 0 0 1 (03) 1 (01)
Immunomodulatory therapy 17 (19) 2 (08) 5 (15) 24 (16)
Conditioning regimen + SCT 0 0 1 (03) 1 (01)
High-dose steroid (mAb) 1 (01) 3 (12) 3 (09) 7 (05)
Clinical trial 30 (34) 5 (19) 24 (70) 59 (40)
Other* 46 (52) 22 (85) 54 (157) 122 (82)
<65 CIT 335 265 (791) 83 56 (675) 109 49 (450) 527 370 (702)
Purine analogue-based CIT 186 (555) 24 (289) 15 (138) 225 (427)
Bendamustine-based CIT 64 (191) 27 (325) 31 (284) 122 (232)
Chlorambucil-based CIT 3 (09) 0 0 3 (06)
CHOP/CVP/CTX-based CIT 10 (30) 4 (48) 2 (18) 16 (30)
Other CIT 2 (06) 1 (12) 1 (09) 4 (08)
Chemotherapy 18 (54) 5 (60) 5 (46) 28 (53)
Chlorambucil monotherapy 4 (12) 1 (12) 0 5 (09)
Anti-CD20 mAb monotherapy 25 (75) 9 (108) 26 (239) 60 (114)
Rituximab monotherapy 23 (69) 8 (96) 14 (128) 45 (85)
Ofatumumab monotherapy 0 0 10 (92) 10 (190)
Immunomodulatory therapy 7 (21) 1 (12) 3 (28) 11 (21)
Conditioning regimen + SCT 0 0 1 (09) 1 (02)
High-dose steroid ( mAb) 0 2 (24) 1 (09) 3 (06)
Clinical trial 9 (27) 2 (24) 5 (46) 16 (30)
Other* 11 (33) 8 (96) 19 (174) 38 (72)
≥65 to <75 CIT 295 192 (651) 82 56 (683) 135 65 (482) 512 313 (611)
Purine analogue-based CIT 100 (339) 20 (244) 17 (126) 137 (268)
Bendamustine-based CIT 73 (248) 31 (378) 43 (319) 147 (287)
Chlorambucil-based CIT 2 (07) 0 0 2 (04)
CHOP/CVP/CTX-based CIT 10 (34) 3 (37) 5 (37) 18 (35)
Other CIT 7 (24) 2 (24) 0 9 (18)
Chemotherapy 29 (98) 4 (49) 14 (104) 47 (92)
Chlorambucil monotherapy 15 (51) 2 (24) 2 (15) 19 (37)
Anti-CD20 mAb monotherapy 34 (115) 15 (183) 23 (170) 72 (141)
Rituximab monotherapy 31 (105) 14 (171) 16 (119) 61 (119)
Ofatumumab monotherapy 2 (07) 0 7 (52) 9 (18)
Immunomodulatory therapy 6 (20) 0 2 (15) 8 (16)
High-dose steroid ( mAb) 0 1 (12) 1 (07) 2 (04)
Clinical trial 13 (44) 1 (12) 13 (96) 27 (53)
Other* 21 (71) 5 (61) 17 (126) 43 (84)
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important insights into whether the results of clinical trials
can be extended to routine community-based treatment.
The survival data represent heterogeneously treated CLL
patient populations in front-line and relapsed settings. As the
data continue to mature, they will provide a unique opportu-
nity for further stratification of outcomes based on clinical/
prognostic factors and clinically relevant comparisons –
particularly those not easily made in the context of clinical
trials.
As this registry enrolled patients between 2010 and 2014,
and enrolment in clinical trials was low (<5%), very few
patients were treated with investigational kinase inhibitor
therapies. The approval of agents, such as ibrutinib and ide-
lalisib, by the United States Food and Drug Administration
has transformed the management of CLL, particularly for
patients with relapsed/refractory (R/R) disease, unfavourable
prognostic factors, or advanced age (for whom CIT regimens
may be too toxic) (Grosicki, 2015; Morabito et al, 2015a,b;
Tucker & Rule, 2015). Landmark studies that contributed to
these approvals and their widespread adoption included ran-
domized comparisons against agents such as chlorambucil,
ofatumumab, and rituximab (Byrd et al, 2014; Furman et al,
Table V. (Continued)
Patients, age (years) Therapy prescribed at enrolment
LOT1 LOT2 LOT≥3 Overall
N n (%) N n (%) N n (%) N n (%)
≥75 CIT 259 131 (506) 95 45 (474) 101 36 (356) 455 212 (466)
Purine analogue-based CIT 46 (178) 21 (221) 4 (40) 71 (156)
Bendamustine-based CIT 65 (251) 17 (179) 27 (267) 109 (240)
Chlorambucil-based CIT 5 (19) 0 1 (10) 6 (13)
CHOP/CVP/CTX-based CIT 13 (50) 6 (63) 2 (20) 21 (46)
Other CIT 2 (08) 1 (11) 2 (20) 5 (11)
Chemotherapy 44 (170) 17 (179) 16 (158) 77 (169)
Chlorambucil monotherapy 22 (85) 3 (32) 9 (89) 34 (75)
Anti-CD20 mAb monotherapy 57 (220) 21 (221) 23 (228) 101 (222)
Rituximab monotherapy 50 (193) 16 (168) 14 (139) 80 (176)
Ofatumumab monotherapy 3 (12) 2 (21) 6 (59) 11 (24)
Kinase inhibitor therapies 0 0 1 (10) 1 (02)
Immunomodulatory therapy 4 (15) 1 (11) 0 5 (11)
High-dose steroid ( mAb) 1 (04) 0 1 (10) 2 (04)
Clinical trial 8 (31) 2 (21) 6 (59) 16 (35)
Other* 14 (54) 9 (95) 18 (178) 41 (90)
CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone; CIT, chemoimmunotherapy; CTX, cyclophosphamide; CVP, cyclophos-
phamide, vincristine, prednisolone; LOT, line of therapy; mAb, monoclonal antibody; SCT, stem cell transplant.
*Other, regimens that were not classifiable as conventional CLL regimens.
Table VI. Purine analogue-based CIT regimens administered at enrolment to the registry.
LOT1 (n = 332) LOT2 (n = 65) LOT≥3 (n = 36) Overall (n = 433)
Purine analogue-based CIT treatment regimen, n (%)
Cladribine + R 0 0 1 (27) 1 (02)
FCR + Dex 8 (24) 1 (15) 2 (56) 11 (25)
FCR + Len 4 (12) 0 0 4 (09)
FC + ofatumumab 0 1 (15) 0 1 (02)
FCR + prednisone 3 (09) 0 0 3 (07)
FCR 230 (693) 34 (523) 18 (500) 282 (651)
FCR + methotrexate 0 1 (15) 0 1 (02)
CR + pentostatin + dexamethasone 1 (03) 0 0 1 (02)
CR + pentostatin 24 (72) 8 (123) 6 (167) 38 (88)
FR + dexamethasone 6 (18) 2 (31) 0 8 (18)
F + ofatumumab 0 0 1 (27) 1 (02)
FR + prednisone 1 (03) 0 1 (27) 2 (05)
FR 55 (166) 18 (277) 7 (194) 80 (185)
CIT, chemoimmunotherapy; CR, cyclophosphamide, rituximab; Dex, dexamethasone; F, fludarabine; FC, fludarabine, cyclophosphamide; FCR,
fludarabine, cyclophosphamide, rituximab; FR, fludarabine, rituximab; Len, lenalidomide; LOT, line of therapy; R, rituximab.
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2014; Sharman et al, 2014b; Hillmen et al, 2015). However,
recent editorials have questioned the clinical equipoise of
such comparisons, particularly when crossover to the experi-
mental arm was not permitted despite overwhelming activity
from previously reported Phase 1b/2 studies (O’Brien, 2013;
Schuster, 2013). Data from the Connect CLL registry were
used to evaluate how frequently these ‘comparator arm’
treatment approaches were prescribed in the community set-
ting. Across all LOTs and all ages, chlorambucil monother-
apy was prescribed to 39% of patients, and ofatumumab
monotherapy to 20% of patients (767% of all prescriptions
were to LOT ≥ 3 patients). Rituximab monotherapy was pre-
scribed to 124% of patients across all LOTs and all ages,
and was most frequently used in the R/R setting (136% of
patients in LOT2/LOT ≥ 3) and in older patients (176% of
patients aged ≥75 years). As the armamentarium of active
agents continues to increase, these data may help to ascertain
which therapies should be used as ‘standard therapy’ controls
in future comparisons.
‘There are several strengths to enrolling only treated patients
to a registry such as this. Firstly, a registry of treated patients
prevents the introduction of bias from uncontrolled systematic
differences that exist between treated and non-treated patients.
Secondly, a registry restricted to treated patients can help to
ensure that the sample size of each treatment subgroup is feasi-
ble for the analysis of real-world treatment patterns and com-
parative effectiveness. There are, however, potential sources of
bias inherent to any observational cohort study arising from
patient selection, data collection, and in assessing treatment
effectiveness due to lack of treatment randomization. There-
fore, the Connect CLL registry made an effort to enrol patients
who were representative of the underlying US population, and
to include patients from multiple geographically diverse and
primarily community-based centres. Patients were enrolled
from a large number of sites distributed widely across the USA
and the number of patients enrolled per site was capped to
ensure a representative sample of CLL patients participated in
the study. In order to further minimize bias and better under-
stand the patient population included in the study, personnel
at sites were educated to consecutively enrol patients as they
entered a line of CLL treatment. Personnel at each centre were
also reminded to invite every eligible patient with CLL to par-
ticipate in the registry, regardless of treatment, medical history
or ECOG PS. Nevertheless, the majority of patients in the
study had an ECOG PS of ≤1 (927%) and were insured either
privately (420%) or through the Medicare program (612%),
which may limit our ability to assess for differences stratified
by performance status and insurance type. In addition,
although enrolling patients only when they started treatment
prevented us from accurately describing all patients diagnosed
with CLL, it did allow us to describe treatment patterns, a
main objective of the registry.
In this analysis of Connect CLL data, important trends in
practice patterns including infrequent use of prognostic test-
ing, marked underutilization of clinical trials, and increasing
use of monotherapies (particularly for R/R patients) were
found. These data reflect real-world practice patterns and the
broad experiences of both community and academic physi-
cians involved in the treatment of CLL patients. These find-
ings may provide physicians with a greater understanding of
the realities of treating CLL patients and the challenges com-
monly encountered in everyday practice. These outcomes will
provide further insights and information to those involved in
the community-based care of patients with CLL.
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